Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Core Laboratories (CLB) EBITDA (2022 - 2025)

Historic EBITDA for Core Laboratories (CLB) over the last 4 years, with Q3 2025 value amounting to $24.5 million.

  • Core Laboratories' EBITDA rose 472.3% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.0 million, marking a year-over-year decrease of 622.81%. This contributed to the annual value of $73.0 million for FY2024, which is 439.13% up from last year.
  • According to the latest figures from Q3 2025, Core Laboratories' EBITDA is $24.5 million, which was up 472.3% from $18.9 million recorded in Q2 2025.
  • In the past 5 years, Core Laboratories' EBITDA ranged from a high of $24.5 million in Q3 2025 and a low of $8.0 million during Q1 2025
  • Moreover, its 4-year median value for EBITDA was $18.6 million (2022), whereas its average is $17.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 4338.11% in 2023, then crashed by 3480.38% in 2025.
  • Quarter analysis of 4 years shows Core Laboratories' EBITDA stood at $19.5 million in 2022, then decreased by 6.12% to $18.3 million in 2023, then decreased by 3.34% to $17.7 million in 2024, then skyrocketed by 38.07% to $24.5 million in 2025.
  • Its last three reported values are $24.5 million in Q3 2025, $18.9 million for Q2 2025, and $8.0 million during Q1 2025.